NCT04858958View on ClinicalTrials.gov

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

December 5, 2024

Study Completion Date

August 31, 2025

Conditions
NSCLC
Interventions
DRUG

Furmonertinib 160mg

randomized to 160mg QD

DRUG

Furmonertinib 240mg

randomized to 240mg QD

Trial Locations (1)

Unknown

Shanghai Chest hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY

NCT04858958 - Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation | Biotech Hunter | Biotech Hunter